Skip to content
OpenCapital
Get started

Ligand Pharmaceuticals LGND Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

General Dynamics logo
General DynamicsGD
9.1M-10.8%
The Travelers Companies logo
The Travelers CompaniesTRV
6.2M-11.6%
Arthur J. Gallagher logo
Arthur J. GallagherAJG
7.6M—
MSCI logo
MSCIMSCI
615K+66.2%
Ametek logo
AmetekAME
2.1M-10.6%
Mondelez International logo
Mondelez InternationalMDLZ
17.8M+3.5%

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%—
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0×0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Ligand Pharmaceuticals (LGND) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $2.22M in Q1 2026.
How has Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, number decreased by 12.1% year-over-year, from $2.53M to $2.22M.
What is the long-term trend for Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Over 3 years (2022 to 2025), Ligand Pharmaceuticals's share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a -12.5% compound annual growth rate (CAGR), from $2.99M to $2M.